| Income Statement | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Loss before income tax | -1,796.195 | -1,124.743 | -1,929.391 | -9,565.648 |
| Income tax benefit | 0 | - | - | - |
| Net loss | -1,796.195 | -1,124.743 | -1,929.391 | -9,565.648 |
| Preferred stock dividends | 976.369 | 813.496 | 751.052 | 777.34 |
| Net loss attributable to common stockholders | -2,772.564 | -1,938.239 | -2,680.443 | -10,342.988 |
| Basic loss per common share | -0.18 | -0.36 | -1.11 | -4.54 |
| Diluted loss per common share | -0.18 | -0.36 | -1.11 | -4.54 |
| Weighted average basic common stock outstanding | 15,698,856 | 5,349,662 | 2,415,089 | 2,275,699 |
| Weighted average diluted common stock outstanding | 15,698,856 | 5,349,662 | 2,415,089 | 2,275,699 |
TNF Pharmaceuticals, Inc. (TNFA)
TNF Pharmaceuticals, Inc. (TNFA)